US 7,531,168 B2
	Method for downmodulating immune response in type I diabetes
Richard M. O'Hara, Jr., Quincy, Mass. (US); and AnnMarie Nagelin, Saugus, Mass. (US)
Assigned to Genetics Institute LLC, Madison, N.J. (US)
Filed on Feb. 15, 2002, as Appl. No. 10/76,934.
Claims priority of provisional application 60/269756, filed on Feb. 16, 2001.
Prior Publication US 2003/0170232 A1, Sep. 11, 2003
Int. Cl. A61K 39/395 (2006.01); C07K 16/00 (2006.01)

U.S. Cl. 424—130.1  [424/133.1; 424/135.1; 424/142.1; 424/143.1; 424/154.1; 530/387.1; 530/387.3; 530/388.15; 530/388.22; 530/388.75]

21 Claims

1. A method of downmodulating an autoimmune response in a subject having type I diabetes, comprising administering an effective amount of an antigen binding portion of an anti-CD28 antibody that blocks signaling via CD28 to the subject, such that an autoimmune response in the subject is downmodulated.